News headlines about Horizon Therapeutics (NASDAQ:HPTX) have been trending somewhat positive recently, according to Accern Sentiment Analysis. Accern scores the sentiment of news coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Horizon Therapeutics earned a news sentiment score of 0.06 on Accern’s scale. Accern also gave headlines about the biopharmaceutical company an impact score of 48.1820065772631 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
Shares of Horizon Therapeutics (HPTX) opened at $45.99 on Thursday. Horizon Therapeutics has a 52 week low of $20.23 and a 52 week high of $46.96. The company has a market capitalization of $964.29 and a price-to-earnings ratio of -1,533.00.
TRADEMARK VIOLATION WARNING: This story was reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this story on another website, it was illegally stolen and republished in violation of United States & international trademark and copyright law. The legal version of this story can be accessed at https://www.dispatchtribunal.com/2018/02/15/horizon-therapeutics-hptx-given-coverage-optimism-rating-of-0-06.html.
About Horizon Therapeutics
Horizon Therapeutics, Inc, formerly Hyperion Therapeutics, Inc, is a biopharmaceutical company. The Company is engaged in the development and commercialization of therapeutics to treat disorders in the areas of orphan diseases. The Company’s products include RAVICTI (glycerol phenylbutyrate) oral liquid, BUPHENYL and AMMONAPS (sodium phenylbutyrate) tablets and powder.
Receive News & Ratings for Horizon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.